A consortium of investors led a €21m round in EvlaBio.

A consortium of investors including Kurma Partners, AdBio Partners, Boehringer Ingelheim Venture Fund, NRW.Venture (NRW.BANK) and HTGF, led a €21m round in EvlaBio, a life science startup. "EvlaBio’s approach is unique in its ability to directly target a key pathway on the cardiomyocyte level. This new therapeutic avenue has the potential to improve lives of millions of patients," Wenzel von der Heydte, EvlaBio CEO and Co-Founder.